Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 18;78(7):613-618.
doi: 10.1093/ajhp/zxab003.

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic

Alyssa M Peckham  1   2 , Jennifer Ball  3   4 , Michelle D Colvard  5 , David Dadiomov  6 , Lucas G Hill  7 , Stephanie D Nichols  8 , Kimberly Tallian  9 , Daniel J Ventricelli  10 , Tran H Tran  11   12
Affiliations

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic

Alyssa M Peckham et al. Am J Health Syst Pharm. .

Abstract

Purpose: Strategies for deploying clinical pharmacists to increase access to buprenorphine in inpatient, outpatient and transitional care, and community practice settings are described.

Summary: Access to medications for opioid use disorder (MOUD) is essential, but patients face many barriers when pursuing treatment and MOUD. The coronavirus disease 2019 (COVID-19) pandemic has compounded the opioid crisis and worsened outcomes by introducing new barriers to MOUD access. Many strategies to ensure continued access to MOUD have been described, but the role of leveraging pharmacists during the opioid/COVID-19 syndemic to improve medication access and outcomes remains underappreciated. Pharmacists, while both qualified and capable of liberalizing access to all forms of MOUD, may have the strongest impact by increasing access to buprenorphine. Herein, we present progressive strategies to maintain and extend buprenorphine access for patients with OUD through deployment of clinical pharmacists, particularly in the context of the COVID-19 pandemic, during which access may be further restricted.

Conclusion: Leveraging pharmacists to extend access to MOUD, particularly buprenorphine, remains an underutilized strategy that should be implemented, particularly during the concurrent COVID-19 global pandemic.

Keywords: COVID-19; buprenorphine; opiate substitution treatment; opioid epidemic; opioid-related disorders; pharmacists.

PubMed Disclaimer

References

    1. Wan W, Long H. ‘Cries for help’: Drug overdoses are soaring during the coronavirus pandemic. Washington Post. https://www.washingtonpost.com/health/2020/07/01/coronavirus-drug-overdose/. Accessed August 18, 2020.
    1. American Medical Association. Issue brief: reports of increases in opioid-related overdose and other concerns during COVID pandemic. https://www.ama-assn.org/system/files/2020-08/issue-brief-increases-in-o.... Accessed August 18, 2020.
    1. Hobson J, Raphelson S. Coronavirus pandemic compounds another ongoing crisis: the opioid epidemic. WBUR website. https://www.wbur.org/hereandnow/2020/07/07/coronavirus-opioid-abuse-crisis. Accessed August 18, 2020.
    1. Wakeman SE, Green TC, Rich J. An overdose surge will compound the COVID-19 pandemic if urgent action is not taken. Nat Med. 2020;26(6):819-820. - PMC - PubMed
    1. National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. National Academies Press; 2019. doi:10.17226/25310 - DOI - PubMed